CVS Health, a household name in pharmacy services, finds itself under the scrutiny of the House Judiciary Committee after a report points to potential antitrust law violations. According to the committee, led by Chair Jim Jordan (R-Ohio), CVS Caremark, the company's pharmacy benefit manager (PBM), may have engaged in bullying independent pharmacies, keeping them from collaborating with third-party services that offer cost-saving options. This information, made public on Wednesday, outlines how CVS leveraged pharmacy network contracts to curtail competition and dissuade these pharmacies from utilizing so-called hub models focused on price transparency and access to specialty medication.
The investigation into CVS Caremark commenced in December 2024, but the internal documents indicate that the company's combative tactics began years earlier. Reported by the House Judiciary Committee, it appears CVS became apprehensive following increased competition from digital pharmacy services like PillPack and Blink, prompting a strategic surveillance of rival hubs in 2019. This fear of lagging in the e-pharmacy space spurred aggressive responses aimed at eliminating competing services and investigative efforts targeting pharmacies that dared collaborate with outside hubs.
The committee's findings suggest that CVS's official reasoning behind these moves—to curb hub system fraud and remove hyperinflated drugs to lower patient costs—lacked conclusive evidence. Rather, internal documents unambiguously showed efforts to strongarm independent pharmacies through audits and legal notices, steering them away from "certain unfavored medication" and making it tougher for them to work with alternative hubs. All the while CVS professed, “We are not opposed to hubs or other innovative models to improve the patient experience," as per David Whitrap, the company's vice president of communications, in a statement, per the House Judiciary Committee.
Despite CVS indicating amends by updating its provider manual in May 2025 to simplify the use of hubs for network pharmacies, suspicions loom as these changes have yet to be seen in practice. The committee report highlighted this concern, stating that "those changes have not yet materialized, and CVS Health is not restricted from reverting to more restrictive provider manual language in the future," indicating an open road for CVS to potentially return to its alleged anticompetitive behavior. Meanwhile, further complicating the pharmaceutical terrain, a Federal Trade Commission report cited the market domination of the "big three" PBMs—CVS Caremark, Cigna’s Express Scripts, and UnitedHealth’s OptumRx—which control roughly 60% of the market and have reportedly driven up the cost of lifesaving medication.
